Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
Summit Therapeutics (SMMT) stock fell 17.31% to a 52-week low after the FDA rejected its lead lung cancer drug, ivonescimab, citing insufficient overall survival data. The FDA stated that progression-free survival gains alone are not enough without statistically significant overall survival improvement. Summit plans to discuss the next steps with the FDA.
How this was made

The 30-second read
Why it matters
The denial removes near‑term commercial upside and forces a reassessment of the company's pipeline valuation.
Market read
The FDA rejection is a material regulatory event that directly impacts Summit's stock price and may influence sentiment toward similar biotech filings.
What to watch
China's prior approval of ivonescimab may provide a non‑U.S. revenue runway that could soften the impact.
Background
Summit Therapeutics (NASDAQ:SMMT) had been developing ivonescimab, a PD‑1 × VEGF bispecific antibody, for NSCLC. The FDA's CRL cites lack of statistically significant overall‑survival improvement.
Ticker impact
Summit Therapeutics received a Complete Response Letter from the FDA rejecting its lead lung‑cancer drug, causing the stock to tumble 17% in pre‑market trading.
likely pressure as the market prices in the regulatory setback
The CRL is a primary regulatory event with immediate price impact; no mitigating news was provided.
Market effects
Biotech and oncology sectors may see broader risk aversion after the denial.
U.S. biotech stocks could face short‑term pressure; Asian markets less affected.
Limited to companies with similar PD‑1/VEGF bispecific programs.
Counterpoint
If the post‑hoc data eventually supports an OS benefit, the stock could rebound on a future resubmission.
Key entities
- companySummit Therapeutics Inc.
Biopharma developing ivonescimab for lung cancer.
- regulatorU.S. Food and Drug Administration
Issued the Complete Response Letter rejecting the BLA.




